Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMH85M0)

Drug Name

ZD-6126 Drug Info

Synonyms

219923-05-4; ZD6126; ZD-6126; UNII-GBO3S6M9W7; GBO3S6M9W7; N-Acetylcochinol-O-phosphate; AZD-6126; N-Acetylcolchicinol dihydrogenphosphate; ZD 6126; SCHEMBL1285000; CHEMBL257662; ANG 453; AZD6126, ANG453; ZINC3993833; AZD 6126; BCP9000366; DB11872; BCP0726000110; ZM 445526; Acetamide, N-((5S)-6,7-dihydro-9,10,11-trimethoxy-3-(phosphonooxy)-5H-dibenzo(a,c)cyclohepten-5-yl)-

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[1]

Cross-matching ID

PubChem CID: 9896434
CAS Number: CAS 219923-05-4
TTD Drug ID: DMH85M0

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Tubulin beta (TUBB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vincristine	DMINOX3	Acute lymphoblastic leukaemia	2A85	Approved	[3]
Albendazole	DMYZ57N	Echinococcus granulosus infectious disease		Approved	[4]
Vindesine	DMVR628	Acute lymphoblastic leukaemia	2A85	Approved	[5]
Taxol	DMUOT9V	Breast cancer	2C60-2C65	Approved	[6]
Mebendazole	DMO14SG	Ascariasis	1F62	Approved	[4]
Plinabulin	DMD7L48	Non-small-cell lung cancer	2C25.Y	Phase 3	[7]
Batabulin	DMHWE5R	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[8]
ABT-751	DMNG35S	Solid tumour/cancer	2A00-2F9Z	Phase 2	[9]
DOLASTATIN-10	DMDUV1S	Solid tumour/cancer	2A00-2F9Z	Phase 2	[10]
BNC-105	DMJC8DR	Mesothelioma	2C51.2	Phase 2	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tubulin beta (TUBB)	TTYFKSZ	NOUNIPROTAC	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00065572) Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV). U.S. National Institutes ofHealth.
2	Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs. 2008 Apr;26(2):159-67.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	Flubendazole interferes with a wide spectrum of cell homeostatic mechanisms in Echinococcus granulosus protoscoleces. Parasitol Int. 2009 Sep;58(3):270-7.
5	Antiproliferating activity of the mitotic inhibitor pironetin against vindesine- and paclitaxel-resistant human small cell lung cancer H69 cells. Anticancer Res. 2007 Mar-Apr;27(2):729-36.
6	Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
7	NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs. 2006 Jan;17(1):25-31.
8	Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier. J Med Chem. 2001 Oct 25;44(22):3599-605.
9	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
10	Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7.
11	The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.Cancer Biol Ther.2014;15(11):1552-60.